149 related articles for article (PubMed ID: 28291776)
1. First-in-human phase 1 of YS110, a monoclonal antibody directed against CD26 in advanced CD26-expressing cancers.
Angevin E; Isambert N; Trillet-Lenoir V; You B; Alexandre J; Zalcman G; Vielh P; Farace F; Valleix F; Podoll T; Kuramochi Y; Miyashita I; Hosono O; Dang NH; Ohnuma K; Yamada T; Kaneko Y; Morimoto C
Br J Cancer; 2017 Apr; 116(9):1126-1134. PubMed ID: 28291776
[TBL] [Abstract][Full Text] [Related]
2. Phase I study of YS110, a recombinant humanized monoclonal antibody to CD26, in Japanese patients with advanced malignant pleural mesothelioma.
Takeda M; Ohe Y; Horinouchi H; Hida T; Shimizu J; Seto T; Nosaki K; Kishimoto T; Miyashita I; Yamada M; Kaneko Y; Morimoto C; Nakagawa K
Lung Cancer; 2019 Nov; 137():64-70. PubMed ID: 31557561
[TBL] [Abstract][Full Text] [Related]
3. Nuclear localization of CD26 induced by a humanized monoclonal antibody inhibits tumor cell growth by modulating of POLR2A transcription.
Yamada K; Hayashi M; Madokoro H; Nishida H; Du W; Ohnuma K; Sakamoto M; Morimoto C; Yamada T
PLoS One; 2013; 8(4):e62304. PubMed ID: 23638030
[TBL] [Abstract][Full Text] [Related]
4. [Development of New Therapy for Malignant Mesothelioma Based on CD26 Molecule].
Morimoto C; Ohnuma K
Gan To Kagaku Ryoho; 2016 Jul; 43(7):855-62. PubMed ID: 27431629
[TBL] [Abstract][Full Text] [Related]
5. Phase 2 Study of YS110, a Recombinant Humanized Anti-CD26 Monoclonal Antibody, in Japanese Patients With Advanced Malignant Pleural Mesothelioma.
Nakagawa K; Kijima T; Okada M; Morise M; Kato M; Hirano K; Fujimoto N; Takenoyama M; Yokouchi H; Ohe Y; Hida T; Aoe K; Kishimoto T; Hirokawa M; Matsuki H; Kaneko Y; Yamada T; Morimoto C; Takeda M
JTO Clin Res Rep; 2021 Jun; 2(6):100178. PubMed ID: 34590026
[TBL] [Abstract][Full Text] [Related]
6. A phase I study of PankoMab-GEX, a humanised glyco-optimised monoclonal antibody to a novel tumour-specific MUC1 glycopeptide epitope in patients with advanced carcinomas.
Fiedler W; DeDosso S; Cresta S; Weidmann J; Tessari A; Salzberg M; Dietrich B; Baumeister H; Goletz S; Gianni L; Sessa C
Eur J Cancer; 2016 Aug; 63():55-63. PubMed ID: 27285281
[TBL] [Abstract][Full Text] [Related]
7. Serum soluble CD26/DPP4 titer variation is a potential prognostic biomarker in cancer therapy with a humanized anti-CD26 antibody.
Kaneko Y; Hatano R; Hirota N; Isambert N; Trillet-Lenoir V; You B; Alexandre J; Zalcman G; Valleix F; Podoll T; Umezawa Y; Takao S; Iwata S; Hosono O; Taguchi T; Yamada T; Dang NH; Ohnuma K; Angevin E; Morimoto C
Biomark Res; 2021 Mar; 9(1):21. PubMed ID: 33757558
[TBL] [Abstract][Full Text] [Related]
8. Safety, pharmacokinetics, and pharmacodynamics of AMG 102, a fully human hepatocyte growth factor-neutralizing monoclonal antibody, in a first-in-human study of patients with advanced solid tumors.
Gordon MS; Sweeney CS; Mendelson DS; Eckhardt SG; Anderson A; Beaupre DM; Branstetter D; Burgess TL; Coxon A; Deng H; Kaplan-Lefko P; Leitch IM; Oliner KS; Yan L; Zhu M; Gore L
Clin Cancer Res; 2010 Jan; 16(2):699-710. PubMed ID: 20068101
[TBL] [Abstract][Full Text] [Related]
9. Phase I study of SS1P, a recombinant anti-mesothelin immunotoxin given as a bolus I.V. infusion to patients with mesothelin-expressing mesothelioma, ovarian, and pancreatic cancers.
Hassan R; Bullock S; Premkumar A; Kreitman RJ; Kindler H; Willingham MC; Pastan I
Clin Cancer Res; 2007 Sep; 13(17):5144-9. PubMed ID: 17785569
[TBL] [Abstract][Full Text] [Related]
10. A humanized anti-CD26 monoclonal antibody inhibits cell growth of malignant mesothelioma via retarded G2/M cell cycle transition.
Hayashi M; Madokoro H; Yamada K; Nishida H; Morimoto C; Sakamoto M; Yamada T
Cancer Cell Int; 2016; 16():35. PubMed ID: 27134571
[TBL] [Abstract][Full Text] [Related]
11. Overexpression of CD26/DPPIV in mesothelioma tissue and mesothelioma cell lines.
Amatya VJ; Takeshima Y; Kushitani K; Yamada T; Morimoto C; Inai K
Oncol Rep; 2011 Dec; 26(6):1369-75. PubMed ID: 21894438
[TBL] [Abstract][Full Text] [Related]
12. Establishment of monoclonal anti-human CD26 antibodies suitable for immunostaining of formalin-fixed tissue.
Hatano R; Yamada T; Matsuoka S; Iwata S; Yamazaki H; Komiya E; Okamoto T; Dang NH; Ohnuma K; Morimoto C
Diagn Pathol; 2014 Feb; 9():30. PubMed ID: 24502396
[TBL] [Abstract][Full Text] [Related]
13. Development of novel monoclonal antibodies with specific binding affinity for denatured human CD26 in formalin-fixed paraffin-embedded and decalcified specimens.
Hatano R; Yamada T; Madokoro H; Otsuka H; Komiya E; Itoh T; Narita Y; Iwata S; Yamazaki H; Matsuoka S; Dang NH; Ohnuma K; Morimoto C
PLoS One; 2019; 14(6):e0218330. PubMed ID: 31194830
[TBL] [Abstract][Full Text] [Related]
14. CD26/dipeptidyl peptidase IV: a comparative study of healthy persons and kidney transplant recipients before and early after transplantation.
Leicht S; Shipkova M; Klett C; Gert H; Altrock E; Wilhelm J; Bolley R; Wollmeyer J; Ender A; Luz B; Olbricht C; Wieland E
Clin Biochem; 2013 Oct; 46(15):1383-8. PubMed ID: 23608353
[TBL] [Abstract][Full Text] [Related]
15. Phase I Dose-Escalation Study of the Anti-CD70 Antibody ARGX-110 in Advanced Malignancies.
Aftimos P; Rolfo C; Rottey S; Offner F; Bron D; Maerevoet M; Soria JC; Moshir M; Dreier T; Van Rompaey L; Michot JM; Silence K; Hultberg A; Gandini D; de Haard H; Ribrag V; Peeters M; Thibault A; Leupin N; Awada A
Clin Cancer Res; 2017 Nov; 23(21):6411-6420. PubMed ID: 28765328
[No Abstract] [Full Text] [Related]
16. Phase 1 study of conatumumab, a pro-apoptotic death receptor 5 agonist antibody, in Japanese patients with advanced solid tumors.
Doi T; Murakami H; Ohtsu A; Fuse N; Yoshino T; Yamamoto N; Boku N; Onozawa Y; Hsu CP; Gorski KS; Friberg G; Kawaguchi T; Sasaki T
Cancer Chemother Pharmacol; 2011 Sep; 68(3):733-41. PubMed ID: 21161528
[TBL] [Abstract][Full Text] [Related]
17. Phase I, pharmacokinetic, and pharmacodynamic study of AMG 479, a fully human monoclonal antibody to insulin-like growth factor receptor 1.
Tolcher AW; Sarantopoulos J; Patnaik A; Papadopoulos K; Lin CC; Rodon J; Murphy B; Roth B; McCaffery I; Gorski KS; Kaiser B; Zhu M; Deng H; Friberg G; Puzanov I
J Clin Oncol; 2009 Dec; 27(34):5800-7. PubMed ID: 19786654
[TBL] [Abstract][Full Text] [Related]
18. Novel Antibody-Drug Conjugate with Anti-CD26 Humanized Monoclonal Antibody and Transcription Factor IIH (TFIIH) Inhibitor, Triptolide, Inhibits Tumor Growth via Impairing mRNA Synthesis.
Hayashi M; Madokoro H; Yamada K; Nishida H; Morimoto C; Sakamoto M; Yanagawa H; Yamada T
Cancers (Basel); 2019 Aug; 11(8):. PubMed ID: 31398954
[TBL] [Abstract][Full Text] [Related]
19. A Phase I First-in-Human Study of Nesvacumab (REGN910), a Fully Human Anti-Angiopoietin-2 (Ang2) Monoclonal Antibody, in Patients with Advanced Solid Tumors.
Papadopoulos KP; Kelley RK; Tolcher AW; Razak AR; Van Loon K; Patnaik A; Bedard PL; Alfaro AA; Beeram M; Adriaens L; Brownstein CM; Lowy I; Kostic A; Trail PA; Gao B; DiCioccio AT; Siu LL
Clin Cancer Res; 2016 Mar; 22(6):1348-55. PubMed ID: 26490310
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of Middle East respiratory syndrome coronavirus infection by anti-CD26 monoclonal antibody.
Ohnuma K; Haagmans BL; Hatano R; Raj VS; Mou H; Iwata S; Dang NH; Bosch BJ; Morimoto C
J Virol; 2013 Dec; 87(24):13892-9. PubMed ID: 24067970
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
